Literature DB >> 3089004

Cost-effective aminoglycoside therapy in surgical patients.

H E Gladen.   

Abstract

There is a risk that the current pressures for hospital cost containment may result in inappropriately restrictive administrative measures. A failure to take into account all factors in estimating the cost of antibiotic therapy yields a greatly distorted view of the importance of acquisition costs. Higher-priced drugs may actually be more cost-effective if they have greater efficacy, wider therapeutic range, and/or are less costly to prepare and administer. Simple microcomputer modeling techniques may be easily employed to examine the economic consequences of therapeutic decisions.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3089004     DOI: 10.1016/0002-9343(86)90506-1

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  3 in total

Review 1.  Aminoglycoside therapy. Current use and future prospects.

Authors:  R Janknegt
Journal:  Pharm Weekbl Sci       Date:  1990-06-22

2.  Cost analysis of imipenem-cilastatin versus clindamycin with tobramycin in the treatment of acute intra-abdominal infection.

Authors:  G de Lissovoy; A Elixhauser; B R Luce; J Weschler; P Mowery; J Reblando; J Solomkin
Journal:  Pharmacoeconomics       Date:  1993-09       Impact factor: 4.981

Review 3.  Antimicrobial therapy. Cost-benefit considerations.

Authors:  B J Guglielmo; G F Brooks
Journal:  Drugs       Date:  1989-10       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.